The short answer
PubMed indexes roughly 34 records on KPV's anti-inflammatory work. The literature is predominantly murine and cell culture, with the alpha-MSH parent literature providing broader context. There is no established human clinical programme.
Key facts
- Indexed records
- ~34 on anti-inflammatory work
- Dominant evidence
- Murine models, cell culture
- Key model paper
- Kannengiesser 2008 (PMID 18092346)
- Delivery work
- Xiao 2017 (PMID 28143741)
- Parent context
- Luger 2003, Brzoska 2010
- Clinical trials
- None established
A small literature with a clear shape
Around 34 indexed records is modest, smaller than Selank's 135, far smaller than DSIP's 519. What it lacks in volume it makes up in consistency: the work runs from mechanism through disease models to delivery, which is a coherent trajectory rather than scattered observations.
The parent literature is larger and relevant
Alpha-MSH has a substantially bigger literature, and Luger's 2003 review in the Annals of the New York Academy of Sciences and Brzoska's 2010 chapter both cover the anti-inflammatory arm. Much of it concerns the whole hormone rather than the tripeptide, so the same read-across caution applies here as for thymosin beta-4 and its 7-residue fragment.
Research material referenced
KPV 10mg, third-party HPLC tested
Searching it
KPV alone returns a mix, since the abbreviation is short and collides with unrelated terms, the same problem that puts an organic acid at the top of a PubChem search. Combining it with peptide or with anti-inflammatory narrows it usefully. Lys-Pro-Val finds chemical records; alpha-MSH finds the parent literature.
What is absent
Human clinical trials. Independent replication across many groups. And a defined molecular target. NF-κB interference is described as an effect rather than mapped to a binding interaction. These gaps are ordinary for a compound at this stage rather than remarkable.
How it compares within this library
Less studied than BPC-157, which has a Phase 2 recruiting, or GHK-Cu with its decades of work. Better motivated than DSIP, whose central claim has never resolved. KPV sits in the middle: a clear rationale, a small consistent literature, and no human data.
Frequently asked questions
How large is the KPV literature?
Roughly 34 indexed records on the anti-inflammatory work, modest, but consistent in direction.
Are there clinical trials?
None established. The evidence is murine models and cell culture.
How should I search for it?
KPV alone collides with unrelated terms. Combine it with peptide or anti-inflammatory, and search Lys-Pro-Val for chemical records.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedKannengiesser K et al. Inflamm Bowel Dis 2008 (PMID 18092346)pubmed.ncbi.nlm.nih.gov
- PubMedXiao B et al. Mol Ther 2017 (PMID 28143741)pubmed.ncbi.nlm.nih.gov
- PubMedLuger TA et al. Ann N Y Acad Sci 2003 (PMID 12851308)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More KPV articles
- KPV Regulatory StatusNo marketing authorisation anywhere. Why an anti-inflammatory literature makes the claims boundary particularly easy to cross.
- The Transporter That Explains the TripeptideKPV is a substrate for PepT1, the intestinal di- and tripeptide transporter. That single fact organises almost everything published about this molecule.
- Delete the Transporter and the Effect DisappearsIn PepT1 knockout mice, KPV produced none of the effect it produced in wild-type animals. That is a stronger mechanistic test than any dose-response curve.
- When the Tripeptide Is the Address, Not the CargoRecent work increasingly attaches KPV to something else - a dye, a nanoparticle, a drug carrier - and uses its affinity to reach cells overexpressing PepT1.
- A Second Claim, With a Different MechanismWork from 2000 reported that alpha-MSH and its KPV fragment inhibited Staphylococcus aureus and Candida albicans. That is not the anti-inflammatory claim.